Strong Buy
Average UserHold
Average AnalystSlightly Bullish
Stock Target AdvisorUSD 39.12
-0.03 (-0.08)%
USD 25.68B
0.42M
USD 36.88(-5.74%)
Strong Buy
Average UserHold
Average AnalystSlightly Bullish
Stock Target AdvisorUSD 25.68B
USD 39.12
Based on the Genmab AS stock forecasts from 13 analysts, the average analyst target price for Genmab AS is USD 36.88 over the next 12 months. Genmab AS’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of Genmab AS is Slightly Bullish , which is based on 8 positive signals and 4 negative signals. At the last closing, Genmab AS’s stock price was USD 39.12. Genmab AS’s stock price has changed by +0.82% over the past week, -7.69% over the past month and +13.00% over the last year.
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease...Read More
0.75
USD 47.50
4.44
USD 26.19
3,125,028
USD 36.61
3,288,558
USD 43.02
N/A
0.17%
6.96%
N/A
Security | Capital Gain | Dividend Return | Total Return |
---|
Symbol | Name | Price(Change) | Market Cap | Price / Earning Ratio | EV/EBITDA |
---|---|---|---|---|---|
|
Vertex Pharmaceuticals Inc | -5.83 (-1.80%) | USD82.14B | 25.24 | 16.84 |
|
Regeneron Pharmaceuticals Inc | -0.47 (-0.06%) | USD80.20B | 15.52 | 12.07 |
|
Moderna Inc | -1.76 (-1.00%) | USD67.64B | 6.64 | 5.34 |
|
Alexion Pharmaceuticals Inc | 0.00 (0.00%) | USD40.34B | 59.23 | 42.56 |
|
BioNTech SE | -0.36 (-0.25%) | USD34.86B | 3.27 | 2.14 |
|
Alnylam Pharmaceuticals Inc | -1.49 (-0.66%) | USD27.73B | N/A | -29.42 |
|
BeiGene Ltd | -1.72 (-0.67%) | USD26.95B | N/A | -9.58 |
|
Seagen Inc | -0.45 (-0.32%) | USD25.90B | 55.02 | -38.86 |
|
Biomarin Pharmaceutical Inc | +1.36 (+1.18%) | USD21.32B | 266.74 | 90.91 |
|
argenx NV ADR | -2.52 (-0.66%) | USD21.13B | N/A | -21.25 |
Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
---|---|---|---|---|---|
|
L&G Pharma Breakthrough U.. | 3.70 % | 0.49 % | -0.10 (-0.93%) | USD0.04B |
|
Legal & General UCITS ETF.. | 3.70 % | 0.49 % | -0.11 (-0.95%) | USD0.04B |
|
L&G Pharma Breakthrough U.. | 3.70 % | 0.00 % | -0.06 (-0.54%) | N/A |
|
First Trust International.. | 2.78 % | 0.60 % | 0.00 (0.00%) | USD6.98M |
|
VanEck Global Healthcare .. | 2.29 % | 0.45 % | -0.03 (-0.29%) | USD0.08B |
|
Evolve Innovation Index F.. | 1.45 % | 0.55 % | +0.70 (+2.39%) | USD0.05B |
|
Evolve Innovation Index F.. | 1.45 % | 0.40 % | 0.00 (0.00%) | N/A |
|
Xtrackers - MSCI Europe M.. | 1.19 % | 0.12 % | +0.46 (+0.34%) | USD0.05B |
|
Deka MSCI Europe MC UCITS.. | 1.19 % | 0.30 % | +0.04 (+0.30%) | USD0.02B |
|
Xtrackers - MSCI Europe M.. | 1.19 % | 0.12 % | -0.46 (-0.34%) | USD0.05B |
|
Deka MSCI Europe MC UCITS.. | 1.19 % | 0.30 % | +0.04 (+0.37%) | USD0.02B |
|
Global X Scientific Beta .. | 0.40 % | 0.39 % | 0.00 (0.00%) | USD3.34M |
Heading 1 | Heading 2 | Heading 3 | Heading 4 | Heading 5 |
---|---|---|---|---|
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
The company had positive total cash flow in the most recent four quarters.
The company had positive total free cash flow in the most recent four quarters.
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
The stock is trading high compared to its peers median on a price to book value basis.
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.